Market News
Recent Developments:
Key Strategic Initiatives:
- On September 8, 2023, MaaT Pharma, a France-based biotechnology company, announced that the European Medicines Agency (EMA) has granted orphan drug designation to MaaT033, an adjunctive and maintenance therapy developed by the MaaT Pharma to improve overall survival in allo-HSCT (Allogeneic Hematopoietic Stem Cell Transplant)
- In May 2023, Astellas Pharma, a global pharmaceutical company, and the Blood and Marrow Transplant Clinical Trials Network (BMT CTN) announced topline results from the Phase 3 MORPHO clinical trial evaluating gilteritinib as a maintenance therapy following allogeneic hematopoietic stem cell transplantation (HSCT) for patients with FMS-like tyrosine kinase 3 (FLT3)-internal tandem duplication (ITD) mutated acute myeloid leukemia (AML)
- In April 2023, Gamida Cell, a global biopharmaceutical company, announced that the company’s allogeneic cell therapy, Omisirge (omidubicel-onlv) has received the U.S. FDA approval for use in adult and pediatric patients 12 years and older with hematologic malignancies planned for umbilical cord blood transplantation following myeloablative conditioning to reduce the time to neutrophil recovery and the incidence of infection
Collaborations & Partnerships:
- In October 2022, Century Therapeutics, a biotechnology company, and Bristol Myers Squibb, a global biopharmaceutical company, announced that the companies have entered into research collaboration and license agreement for the development and commercialization of pluripotent stem cell (iPSC) derived, engineered natural killer cell (iNK) and/or T cell (iT) programs for hematologic malignancies and solid tumors
U.S.: 
U.K. : 
India : 